Table 4.

Absorbsion properties of molecules

	Desloratadine	Levocetirizine	Fexofenadine	CAPE	Quercetin	Melatonin	Curcumin	Vit C
Caco-2 Permeability	− 4.889	− 5.597	− 5.098	− 5.216	− 6.177	− 4.835	− 5.417	− 5.883
MDCK Permeability	− 5.015	− 4.971	− 4.838	− 4.727	− 4.923	− 4.571	− 4.936	− 4.28
PAMPA	0.072	0.853	0.953	0.169	0.581	0.33	0.124	0.908
Pgp-inhibitor	0.87	0.011	0.025	0.428	0.028	0.236	0.022	0.0
Pgp-Substrate	0.847	0.394	0.999	0.014	0.031	0.099	0.004	0.137
HIA	0.0	0.0	0.0	0.163	0.134	0.606	0.005	0.283
F20%	0.0	0.0	0.988	0.915	0.504	0.255	0.485	0.328
F30%	0.005	0.0	0.99	0.952	0.991	0.063	0.465	0.709
F50%	0.023	0.0	0.999	0.982	0.999	0.705	1.0	0.694

Caco-2: Optimal: higher than −5.15 Log unit;

MDCK: low permeability: < 2 × 10–6 cm/s, medium permeability: 2–20 × 10–6 cm/s, high passive permeability: > 20 × 10–6 cm/s

PAMPA: The experimental data for Peff was logarithmically transformed (logPeff), Molecules with log Peff values below 2.0 were cla Category 1: Inhibitor;

Pgp-inhibitor and Pgp-Substrate: Category 1: Inhibitor; Category 0: Non-inhibitor; The output value is the probability of being

Pgp-inhibitor and Pgp-substrate

HIA: Human Intestinal Absorption, Category 1: HIA+ (HIA < 30%); Category 0: HIA-( HIA ≥ 30%);The output value is the probability of being HIA+

F20%: Category 1: F 20%+ (bioavailability < 20%);Category 0: F 20%− (bioavailability ≥ 20%);The output value is the probability of being F 20%+

F 30%:Category 1: F 30%+ (bioavailability < 30%); Category 0: F 30%− (bioavailability ≥ 30%);The output value is the probability of being F 30%+

F50%: Category 1: F 50%+ (bioavailability < 50%); Category 0: F 50%− (bioavailability ≥ 50%);The output value is the probability of being F 50%+